Europe eyes arthritis drug for COVID-19 cases
Published:Monday | August 16, 2021 | 10:29 AM
AMSTERDAM — The European Medicines Agency has started an accelerated review process to determine if a common arthritis drug might help people hospitalised with severe COVID-19, months after the drug was granted an emergency use authorisation in the United States.
In a statement Monday, the EU drug regulator said it was assessing an application to extend the use of tocilizumab for adults suffering from severe coronavirus in the hospital, who were already being treated with other steroids or required extra oxygen, including via a ventilator.
Tocilizumab is an anti-inflammatory drug currently used to treat adults and children with severe arthritis.
In June, the US Food and Drug Administration granted the drug an emergency use authorisation and the World Health Organization recommended its use last month for people who are critically ill with COVID-19.
The European regulator said it expected to make a decision by mid-October on tocilizumab, based on data from four large studies.
The drug was first licensed in the EU in 2009.
Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.